SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Junehawk Lee, Doheon Lee, Association analysis of the perturbation of interactions in biological pathways and anticancer drug activity, Biochemical and Biophysical Research Communications, 2016, 470, 1, 137

    CrossRef

  2. 2
    Kimberly M. Komatsubara, Richard D. Carvajal, Selumetinib for the treatment of melanoma, Expert Opinion on Orphan Drugs, 2016, 1

    CrossRef

  3. 3
    Z Eroglu, H A Tawbi, J Hu, M Guan, P H Frankel, N H Ruel, S Wilczynski, S Christensen, D R Gandara, W A Chow, A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas, British Journal of Cancer, 2015, 112, 10, 1644

    CrossRef

  4. 4
    J. S. Fowles, C. L. Denton, D. L. Gustafson, Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma, Veterinary and Comparative Oncology, 2015, 13, 3
  5. 5
    Ian E Templeton, Luna Musib, MEK inhibitors beyond monotherapy: current and future development, Current Opinion in Pharmacology, 2015, 23, 61

    CrossRef

  6. 6
    Mark Noble, Margot Mayer-Pröschel, Zaibo Li, Tiefei Dong, Wanchang Cui, Christoph Pröschel, Ibro Ambeskovic, Joerg Dietrich, Ruolan Han, Yin Miranda Yang, Christopher Folts, Jennifer Stripay, Hsing-Yu Chen, Brett M. Stevens, Redox biology in normal cells and cancer: Restoring function of the redox/Fyn/c-Cbl pathway in cancer cells offers new approaches to cancer treatment, Free Radical Biology and Medicine, 2015, 79, 300

    CrossRef

  7. 7
    Koji Tsumagari, Zakaria Y. Abd Elmageed, Andrew B. Sholl, Paul Friedlander, Mohamed Abdraboh, Mingzhao Xing, A. Hamid Boulares, Emad Kandil, Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer, Cancer Letters, 2015, 368, 1, 46

    CrossRef

  8. 8
    Yutaka Sugihara, Ákos Végvári, Charlotte Welinder, Göran Jönsson, Christian Ingvar, Lotta Lundgren, Håkan Olsson, Thomas Breslin, Elisabet Wieslander, Thomas Laurell, Melinda Rezeli, Bo Jansson, Toshihide Nishimura, Thomas E. Fehniger, Bo Baldetorp, György Marko-Varga, A new look at drugs targeting malignant melanoma—An application for mass spectrometry imaging, PROTEOMICS, 2014, 14, 17-18
  9. 9
    Katharina Amschler, Luise Erpenbeck, Sebastian Kruss, Michael P. Schön, Nanoscale Integrin Ligand Patterns Determine Melanoma Cell Behavior, ACS Nano, 2014, 8, 9, 9113

    CrossRef

  10. 10
    Mario Mandalà, Barbara Merelli, Daniela Massi, Nras in melanoma: Targeting the undruggable target, Critical Reviews in Oncology/Hematology, 2014, 92, 2, 107

    CrossRef

  11. 11
    Silvina Grasso, Elena Tristante, Miguel Saceda, Pablo Carbonell, Leticia Mayor-López, Mar Carballo-Santana, Estefanía Carrasco-García, Lourdes Rocamora-Reverte, Pilar García-Morales, Fernando Carballo, José A. Ferragut, Isabel Martínez-Lacaci, Resistance to Selumetinib (AZD6244) in Colorectal Cancer Cell Lines is Mediated by p70S6K and RPS6 Activation, Neoplasia, 2014, 16, 10, 845

    CrossRef

  12. 12
    Atsushi Kato, Kathryn E. Hulse, Bruce K. Tan, Robert P. Schleimer, B-lymphocyte lineage cells and the respiratory system, Journal of Allergy and Clinical Immunology, 2013, 131, 4, 933

    CrossRef

  13. 13
    Lucio Tentori, Pedro Miguel Lacal, Grazia Graziani, Challenging resistance mechanisms to therapies for metastatic melanoma, Trends in Pharmacological Sciences, 2013, 34, 12, 656

    CrossRef

  14. 14
    Amanda D. Bucheit, Erica Syklawer, John A. Jakob, Roland L. Bassett, Jonathan L. Curry, Jeffrey E. Gershenwald, Kevin B. Kim, Patrick Hwu, Alexander J. Lazar, Michael A. Davies, Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma, Cancer, 2013, 119, 21
  15. 15
    April K. S. Salama, Kevin B. Kim, MEK Inhibition in the Treatment of Advanced Melanoma, Current Oncology Reports, 2013, 15, 5, 473

    CrossRef

  16. 16
    Zahava Siegfried, Serena Bonomi, Claudia Ghigna, Rotem Karni, Regulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in Cancer, International Journal of Cell Biology, 2013, 2013, 1

    CrossRef

  17. You have free access to this content17
    Matthew J Sale, Simon J Cook, That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance, British Journal of Pharmacology, 2013, 169, 8